MedPath

M. Arkin (1999) Ltd.

🇮🇱Israel
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

Phase 1
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Placebo
Drug: ARK-E021 5%
Drug: ARK-E021 10%
First Posted Date
2011-12-16
Last Posted Date
2013-12-03
Lead Sponsor
M. Arkin 1999 Ltd.
Target Recruit Count
157
Registration Number
NCT01494285
Locations
🇮🇱

HaEmek Medical Center, Afula, Israel

🇮🇱

Meir Medical Center, Kfar Saba, Israel

🇮🇱

Souraski Medical Center, Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath
M. Arkin (1999) Ltd. | MedPath